Extraneal

Adult administration

For intraperitoneal use only and not for intravenous use. It is a single-dose product. Replace existing peritoneal dialysis fluid once daily during a 24-hour period. The administered dose should not typically exceed 2.0L for adult patients, and 1.5L should be used in case of abdominal distension. The recommended dwell time is between 6-12 hours for CAPD and 14-16 hours for APD. The peritoneal dialysis process should be conducted aseptically.

Child administration

The safety and efficacy in children under 18 years have not been evaluated, and therefore it is not recommended.

This medication should not be used in patients who are allergic to starch polymers or icodextrin. Patients with hypersensitivity to maltose or isomaltose should also not use this medication. Patients with poor condition after abdominal surgery or problems with peritoneal function, patients with glycogen storage disease, diaphragm injury, etc., should not be administered this medication. Lactate metabolism patients, severe lactic acidosis patients, and patients with uremia-related hemorrhagic diathesis are also excluded from administration. Pregnant or breastfeeding women, children, and patients with acute kidney failure should use this medication with caution, and patients with specific peritoneal and abdominal diseases also require attention. This medication is used only for peritoneal dialysis, and fluid balance must be accurately recorded and weight changes carefully monitored. In particular, the patient's condition must be meticulously monitored to avoid excess or deficiency of fluid. During dialysis, protein, amino acids, and vitamins may be lost, so supplementation therapy should be performed according to the physician's prescription if necessary. Diabetic patients who require blood sugar control must regularly check their blood sugar levels and adjust their insulin doses, and they should use a method that does not interact with maltose when measuring blood sugar. Various adverse reactions such as peritonitis, infections, skin rashes, blood pressure changes, gastrointestinal symptoms, and neurological abnormalities may occur, so symptoms should be immediately reported to medical personnel. This medication may interact with other drugs, so if other medications are being taken, it is essential to consult with a healthcare professional. Pregnant or breastfeeding women should avoid using this medication unless under special circumstances, and its use in pediatric patients is not recommended. In case of overdose, medical personnel should be notified immediately and appropriate measures should be taken, and this medication must always be used under the supervision of a physician. When exchanging peritoneal dialysis fluid, aseptic technique must be strictly adhered to, and the solution must be appropriately warmed before use; discolored or damaged solutions should not be used. Keep out of reach of children and discard any leftover solutions after use.

Serious side effects

• Urticaria
• angioedema
• generalized urticaria
• toxic epidermal necrolysis
• vasculitis
• serum sickness
• erythema multiforme
• anaphylaxis/anaphylactoid reactions
• dyspnea
• respiratory distress

Mild side effects

• Influenza
• furuncles
• infections
• anemia
• leukocytosis
• eosinophilia
• parathyroid dysfunction
• dehydration
• hypovolemia
• hypoglycemia

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, and the temperature should be maintained below 30 degrees. Storing it this way helps to preserve the medication's efficacy and prevent degradation.

Appearance

This medication is a transparent peritoneal dialysis solution, light yellow in color, contained in a colorless transparent plastic bag. 2L/bag (Automated Peritoneal Dialysis) is connected in the order of infusion line, inner plug, connector, and rubber ring to the peritoneal dialysis solution bag.

Package unit

2000ml/2 bags, 2000ml/bag